Niyondiko, N. (2024) Clinical Management of Diabetic Ketoacidosis in Pregnancy: A Review of Current Literature. Open Access Library Journal, 11, 1-25. doi: 10.4236/oalib.1112246 .

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Dawe, a self-proclaimed “massive foodie,” suddenly found herself unable to eat a single thing. “It was really scary – I just ...

While Ozempic itself is approved for the treatment of diabetes, it's often prescribed off-label to ... Now, multiple studies have identified a link between weight-loss drugs and gastroparesis, a ...

GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-yearStrong cumulative ...

Evoke Pharma Inc. is a specialty pharmaceutical company based in Delaware, primarily focused on the development and commercialization of drugs for gastroenterological disorders, notably through its ...

It is driven by rising diabetes rates. The global gastroparesis drugs market is set to grow by $1.42b from 2024 to 2028, with ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. The loss of insulin leads to the ...

Gastroparesis is a chronic disorder that affects a significant subset of the population. Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the ...

Braden Kuo has received funding from Evoke Pharmaceuticals to carry out clinical trials into the development of intranasal metoclopramide for diabetic gastroparesis. The authors have no other ...